BR0313161A - Composto, composição farmacêutica, e, uso de uma quantidade eficaz de hemiidrato de (r)-(6-(1-((4-fluorobenzil)metilamino]etilidenoamino)-2 (r)-hidroxiindan-1-il) amida do ácido bifenil-4-carboxìlico - Google Patents
Composto, composição farmacêutica, e, uso de uma quantidade eficaz de hemiidrato de (r)-(6-(1-((4-fluorobenzil)metilamino]etilidenoamino)-2 (r)-hidroxiindan-1-il) amida do ácido bifenil-4-carboxìlicoInfo
- Publication number
- BR0313161A BR0313161A BR0313161-0A BR0313161A BR0313161A BR 0313161 A BR0313161 A BR 0313161A BR 0313161 A BR0313161 A BR 0313161A BR 0313161 A BR0313161 A BR 0313161A
- Authority
- BR
- Brazil
- Prior art keywords
- fluorobenzyl
- biphenyl
- ethylidenoamino
- hydroxyindan
- methylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40544302P | 2002-08-22 | 2002-08-22 | |
| PCT/US2003/023260 WO2004018411A1 (en) | 2002-08-22 | 2003-08-12 | Muscarinic agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313161A true BR0313161A (pt) | 2005-06-14 |
Family
ID=31946873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313161-0A BR0313161A (pt) | 2002-08-22 | 2003-08-12 | Composto, composição farmacêutica, e, uso de uma quantidade eficaz de hemiidrato de (r)-(6-(1-((4-fluorobenzil)metilamino]etilidenoamino)-2 (r)-hidroxiindan-1-il) amida do ácido bifenil-4-carboxìlico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7160922B2 (https=) |
| EP (1) | EP1534667B1 (https=) |
| JP (1) | JP4469280B2 (https=) |
| CN (1) | CN100554247C (https=) |
| AR (1) | AR040889A1 (https=) |
| AT (1) | ATE491683T1 (https=) |
| AU (1) | AU2003256791B2 (https=) |
| BR (1) | BR0313161A (https=) |
| CA (1) | CA2493958C (https=) |
| CY (1) | CY1111115T1 (https=) |
| DE (1) | DE60335380D1 (https=) |
| DK (1) | DK1534667T3 (https=) |
| ES (1) | ES2355213T3 (https=) |
| MX (1) | MXPA05002080A (https=) |
| PE (1) | PE20040894A1 (https=) |
| PT (1) | PT1534667E (https=) |
| SI (1) | SI1534667T1 (https=) |
| TW (1) | TW200410922A (https=) |
| WO (1) | WO2004018411A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275095A3 (en) * | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| JP2013523679A (ja) | 2010-03-29 | 2013-06-17 | ビーエーエスエフ ソシエタス・ヨーロピア | 殺菌性イミノ誘導体 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76492C2 (en) * | 2001-09-21 | 2006-08-15 | Lilly Co Eli | Muscarinic agonists, a pharmaceutical composition on their basis |
-
2003
- 2003-08-12 DE DE60335380T patent/DE60335380D1/de not_active Expired - Lifetime
- 2003-08-12 JP JP2004530846A patent/JP4469280B2/ja not_active Expired - Fee Related
- 2003-08-12 AU AU2003256791A patent/AU2003256791B2/en not_active Ceased
- 2003-08-12 CA CA2493958A patent/CA2493958C/en not_active Expired - Fee Related
- 2003-08-12 EP EP03792989A patent/EP1534667B1/en not_active Expired - Lifetime
- 2003-08-12 US US10/524,960 patent/US7160922B2/en not_active Expired - Fee Related
- 2003-08-12 BR BR0313161-0A patent/BR0313161A/pt not_active IP Right Cessation
- 2003-08-12 DK DK03792989.0T patent/DK1534667T3/da active
- 2003-08-12 CN CNB038192500A patent/CN100554247C/zh not_active Expired - Fee Related
- 2003-08-12 PT PT03792989T patent/PT1534667E/pt unknown
- 2003-08-12 SI SI200331933T patent/SI1534667T1/sl unknown
- 2003-08-12 WO PCT/US2003/023260 patent/WO2004018411A1/en not_active Ceased
- 2003-08-12 AT AT03792989T patent/ATE491683T1/de active
- 2003-08-12 MX MXPA05002080A patent/MXPA05002080A/es active IP Right Grant
- 2003-08-12 ES ES03792989T patent/ES2355213T3/es not_active Expired - Lifetime
- 2003-08-20 TW TW092122893A patent/TW200410922A/zh unknown
- 2003-08-20 AR AR20030103011A patent/AR040889A1/es unknown
- 2003-08-21 PE PE2003000851A patent/PE20040894A1/es not_active Application Discontinuation
-
2011
- 2011-01-19 CY CY20111100057T patent/CY1111115T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2493958A1 (en) | 2004-03-04 |
| WO2004018411A1 (en) | 2004-03-04 |
| CN1675173A (zh) | 2005-09-28 |
| ES2355213T3 (es) | 2011-03-23 |
| CY1111115T1 (el) | 2015-06-11 |
| JP2005536549A (ja) | 2005-12-02 |
| MXPA05002080A (es) | 2005-08-18 |
| PE20040894A1 (es) | 2004-11-25 |
| CN100554247C (zh) | 2009-10-28 |
| AR040889A1 (es) | 2005-04-20 |
| DK1534667T3 (da) | 2011-02-14 |
| DE60335380D1 (de) | 2011-01-27 |
| US7160922B2 (en) | 2007-01-09 |
| TW200410922A (en) | 2004-07-01 |
| EP1534667B1 (en) | 2010-12-15 |
| JP4469280B2 (ja) | 2010-05-26 |
| EP1534667A1 (en) | 2005-06-01 |
| AU2003256791A1 (en) | 2004-03-11 |
| ATE491683T1 (de) | 2011-01-15 |
| AU2003256791B2 (en) | 2008-12-11 |
| US20060122280A1 (en) | 2006-06-08 |
| CA2493958C (en) | 2010-11-09 |
| SI1534667T1 (sl) | 2011-02-28 |
| PT1534667E (pt) | 2011-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0212733A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo | |
| BR0206433A (pt) | Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto | |
| BR0212277A (pt) | Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor do ibat, e, composição farmacêutica | |
| BR0212183A (pt) | Composto, método e composição para o controle de uma praga invertebrada | |
| BR0212345A (pt) | Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor de ácido de bile ileal em um animal de sangue quente e composição farmacêutica | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| BRPI0518459A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| BR0300500B1 (pt) | composiÇço poliolefÍnica, processo para estabilizaÇço de uma poliolefina e uso de uma mistura. | |
| BR0313160A (pt) | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto | |
| MY136800A (en) | Inhibitors of the interaction between mdm2 and p53 | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR0109577A (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para tratar cânceres em um animal de sangue quente | |
| DK1767535T3 (da) | Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse | |
| BR0202518A (pt) | Método para produção de uma composição, composição, e, método para aderir um material a um substrato | |
| UY25143A1 (es) | Procedimiento para la preparacion de inhibidores de proteasas. | |
| EA200400280A1 (ru) | Новые неочищенные и кристаллические формы гидрохлорида лерканидипина | |
| CR10974A (es) | Inhibidores de carboxipeptidasa b plasmatica (divisional) | |
| BRPI0415010A (pt) | forma cristalina, composto, processo para preparar os mesmos, métodos para tratar uma condição associada com excesso de taquicininas, uso do composto cristalino, e, composição farmacêutica | |
| BR0317229A (pt) | Composição e uso de agonista completo de alfa7nachr | |
| MXPA05013751A (es) | Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales. | |
| EE200400031A (et) | Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat | |
| BR0208813A (pt) | Composições contendo imidazotriazinona para a aplicação nasal | |
| BRPI0411308A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| BR0313161A (pt) | Composto, composição farmacêutica, e, uso de uma quantidade eficaz de hemiidrato de (r)-(6-(1-((4-fluorobenzil)metilamino]etilidenoamino)-2 (r)-hidroxiindan-1-il) amida do ácido bifenil-4-carboxìlico | |
| BR0011339A (pt) | Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE REIVINDICADA (US 60/405,443), POR NAO ESTAR EM CONFORMIDADE COM O PREVISTO NOS 6O E 7O DO ART.16 DA LPI/96. |
|
| B150 | Others concerning applications: publication cancelled [chapter 15.30 patent gazette] |
Free format text: ANULADO O DESPACHO (15.9) DA RPI 2017, POR TER SIDO REALIZADO INDEVIDAMENTE. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014. |